Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

GSK aims for one billion doses of booster as COVID-19 vaccine race heats up

share with twitter share with LinkedIn share with facebook
05/28/2020 | 07:48am EDT
FILE PHOTO: A GSK logo is seen at the GSK research centre in Stevenage

By Pushkala Aripaka, Aakash B and Ludwig Burger

GSK, the world's largest vaccine maker, laid out plans on Thursday to produce 1 billion doses of vaccine efficacy boosters for COVID-19 shots next year, as the race to develop a successful solution to the coronavirus crisis heats up.

The British drugmaker said it was in talks with governments to back the manufacturing expansion of the boosters, or adjuvants, that would help to scale up production of future vaccines for COVID-19, the disease caused by the novel coronavirus.

The adjuvant could be a critical ingredient in at least seven experimental vaccines against the new coronavirus currently being developed around the world, including one by Sanofi, with whom GSK signed a collaboration deal in April.

Adjuvants, a key component of the traditional vaccination approach, have been shown to create stronger and longer-lasting immunity against infections and allow for lower dosing of the protein in a vaccine, making way for higher-volume production.

GSK would not disclose the programme's costs, saying only that production would take place at sites in Europe and North America and that it would reinvest any profit into coronavirus research and preparation for future pandemics.

The company is one of the many global players working on projects to counter the respiratory illness that currently that has no treatment and has killed about 350,000 people.

"We believe that more than one vaccine will be needed to address this global pandemic and we are working with partners around the world to do so," said GSK Global Vaccines President Roger Connor.

As well as its collaboration with Sanofi, GSK has contributed the adjuvant to alliances involving Chinese biotech firms Clover Biopharmaceuticals and Xiamen Innovax, as well as the University of Queensland, Australia.

GSK shares were up 1.4% at 1,671.2 pence by 0916 GMT.


Experts have predicted that a successful vaccine will take more than a year to develop. Companies and governments are pouring money into dozens of programmes as their best hope of allowing an escape from lockdowns and getting economies expanding again.

While more than 100 vaccine candidates are being trialled, according to the World Health Organisation only 10 have moved to testing in humans, a stage where they are investigated for safety and efficacy, and at which most vaccines fail.


Other promising vaccine approaches do without adjuvants. These include the use of so-called mRNA, pursued by Moderna and Biontech, where genetic code is injected into the body to instruct human cells to make virus-like proteins that trigger an immune response.

AstraZeneca and Oxford University's viral vector approach, where harmless viruses instruct human cells to make virus-like proteins, also needs no adjuvants.

The United States last week secured almost a third of the first 1 billion doses planned for AstraZeneca's experimental COVID-19 vaccine by pledging up to $1.2 billion.

On Thursday GSK said that making its adjuvant available to the world's poorest countries will be a key part of its efforts.

(Reporting by Pushkala Aripaka and Aakash Jagadeesh Babu in Bengaluru and Ludwig Burger in Frankfurt; Additional reporting by Kate Kelland in London; Editing by Shounak Dasgupta, David Goodman and Jan Harvey)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.15% 7943 Delayed Quote.4.42%
BEST INC. -5.26% 2.88 Delayed Quote.-48.20%
BIONTECH SE 2.70% 88.69 Delayed Quote.161.78%
GLAXOSMITHKLINE PLC 0.80% 1343.8 Delayed Quote.-24.46%
HOPE, INC. -4.38% 5900 End-of-day quote.83.23%
INNOVAX HOLDINGS LIMITED 10.53% 0.42 End-of-day quote.-88.59%
MODERNA, INC. -0.44% 70.53 Delayed Quote.260.58%
SANOFI 0.24% 82.94 Real-time Quote.-7.45%
THE GLOBAL LTD. -0.92% 216 End-of-day quote.-54.14%
THE NEW HOME COMPANY INC. 0.60% 5.06 Delayed Quote.8.58%
VECTOR INC. -0.95% 209 End-of-day quote.-36.47%
VECTOR INC. -0.88% 1009 End-of-day quote.-5.35%
WORLD CO., LTD. 1.31% 1397 End-of-day quote.-48.09%
share with twitter share with LinkedIn share with facebook
12:16aTo Find a Coronavirus Vaccine, GlaxoSmithKline Is -2-
12:16aTo Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Co..
10/23Canada to invest up to C$214 mln for research into domestic-made vaccines - P..
10/23GLAXOSMITHKLINE : GSK - ViiV Healthcare presents continued positive findings fro..
10/23Noveome Biotherapeutics, Inc. Announces New Appointments to its Board of Dire..
10/23GLAXOSMITHKLINE PLC : quaterly earnings release
10/23GLAXOSMITHKLINE : Gets a Neutral rating from Credit Suisse
10/22European cities plead for more flu shots as winter looms, pandemic rages
10/22GLAXOSMITHKLINE : ViiV Healthcare presents positive new findings from two studie..
10/22GLAXOSMITHKLINE : ViiV Healthcare presents continued positive findings from firs..
More news
Sales 2020 34 651 M 45 178 M 45 178 M
Net income 2020 4 791 M 6 246 M 6 246 M
Net Debt 2020 22 730 M 29 635 M 29 635 M
P/E ratio 2020 13,9x
Yield 2020 5,95%
Capitalization 66 890 M 87 270 M 87 211 M
EV / Sales 2020 2,59x
EV / Sales 2021 2,46x
Nbr of Employees 99 437
Free-Float 91,3%
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 1 806,25 GBX
Last Close Price 1 343,80 GBX
Spread / Highest target 74,9%
Spread / Average Target 34,4%
Spread / Lowest Target -16,7%
EPS Revisions
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.43%381 970
ROCHE HOLDING AG-5.33%280 343
PFIZER INC.-2.55%207 994
MERCK & CO., INC.-12.23%200 341
NOVARTIS AG-16.62%186 175